Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • 4′-deoxydoxorubicin  (1)
  • Adjuvante, perioperative Chemotherapie  (1)
  • Castleman's disease  (1)
  • G-CSF  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Hodgkin's and Castleman's disease in a patient with systemic mastocytosis (1999)
    Springer
    Annals of hematology 78 (1999), S. 97-100 
    Details
    ISSN: 1432-0584
    Keywords: Key words Systemic mastocytosis ; Hodgkin's disease ; Castleman's disease ; Chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract  Systemic mastocytosis is a rare condition characterized clinically by the local consequences of vasoactive peptides released from infiltrating mast cells in the reticuloendothelial tissues. Mast cells originate from the pluripotent bone marrow stem cells; it is therefore not surprising that myeloproliferative and myelodysplastic disorders commonly coexist or terminate the clinical phase of mastocytosis. We report here, to our knowledge, the first case of Hodgkin's and Castleman's disease occurring in a patient with co-existent systemic mastocytosis, which remained unchanged after combination chemotherapy for Hodgkin's disease.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/s002770050482
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer (1997)
    Springer
    Annals of oncology 8 (1997), S. 655-661 
    Details
    ISSN: 1569-8041
    Keywords: breast cancer ; cyclophosphamide ; G-CSF ; paclitaxel
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: The toxicity profile of prolonged infusions of paclitaxel incombination with cyclophosphamide in metastatic breast cancer has already beendefined. The objective of this dose-finding study was to determine the maximumtolerable doses (MTDs) of shorter (three-hour) infusions of paclitaxel incombination with i.v. bolus cyclophosphamide in patients who had previouslyreceived a maximum of one chemotherapy for advanced breast carcinoma. The MTDof the same regimen with granulocyte colony-stimulating factor (G-CSF) supportwas then established. Patients and methods: Eighty women with metastatic breast cancer receiveda total of 352 fully evaluable courses of therapy. The starting doses werepaclitaxel 135 mg/m2 and cyclophosphamide 750mg/m2 given every three weeks. At least three patients weretreated at each dose level and if there were dose-limiting toxic effectsduring the first cycles three additional patients were entered. G-CSF support(5µg/kg s.c.) was added to the second cycle if specific dose-limitingtoxicitieshad occurred during the first cycle. The MTD was defined as the dose level atwhich more than two of six patients presented dose-limiting toxicities duringthe first cycle. Results: Febrile neutropenia (n = 4) and severe thrombocytopenia (n = 1)defined the MTDs of paclitaxel as 200 mg/m2 and ofcyclophosphamide as 2,000 mg/m2, with or without G-CSF inpatients with and, respectively, without prior chemotherapy for advanceddisease. Non-hematologic toxicity was moderate. Recommended doses were 200mg/m2 of paclitaxel and 1,750 mg/m2 ofcyclophosphamide with or without G-CSF in patients with and, respectively,without prior chemotherapy. The overall response rate was 25% and50%, respectively, in patients with and without prior chemotherapy formetastatic disease. Complete remissions (9%) were reported only inpatients without prior chemotherapy; antitumour activity in women withanthracycline-resistant disease, with an 8% response rate (95%CI: 1%–26%), was poor. Conclusions: Paclitaxel at 200 mg/m2 and cyclophosphamideat 1,750 mg/m2 can be safely administered every three weeksto women with advanced breast cancer. The moderate antitumour activityobserved with the schedule tested argues against its use as initial therapyfor advanced breast cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008211629858
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    263. Adjuvante portale Chemotherapie bei colorectalen Carcinomen, eine multizenterstudie der schweizerischen arbeitsgemeinschaft für klinische krebsforschung (SAKK) (1987)
    Springer
    Langenbeck's archives of surgery 372 (1987), S. 889-889 
    Details
    ISSN: 1435-2451
    Keywords: Adenocarcinoma of the colon and rectum ; Adjuvant perioperative liver infusion ; Liver metastases ; Colorectales Carcinom ; Adjuvante, perioperative Chemotherapie ; Lebermetastasen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Untersucht wird beim colorectalen Carcinom die Wirkung einer perioperativen portalen Leberperfusion mit 5-Fluorouracil und Mitomycin C. Zur Zeit sind 409 Patienten auswertbar, 202 im Kontroll- und 207 im Behandlungsarm. Die bisherigen Resultate (März 87), bei einer Beobachtungszeit von 35 Monaten, zeigen im Behandlungsarm eine deutlich geringere Tendenz für Lebermetastasen (10,4% vs 6,3%), besonders auch in den Untergruppen (Colon 11,5% vs 6,8% und Dukes' C: 22,2% vs 6,9%). Entsprechend ist auch der Carcinom-Tod seltener (14,4% vs 12,1%; 15,8% vs 8,5% und 25,4% vs 15,5%). Die Beobachtungszeit ist für eine statistische Analyse noch zu kurz.
    Notes: Summary The efficacy of adjuvant, perioperative portal liver infusion with 5-fluorouracil and mitomycin C was investigated (409 patients, 202 control subjects, 207 treated). Liver metastases were detected in 10.4% of the untreated vs 6.3% of the treated patients. The median follow-up was 35 months. For the colon subgroups (excluding the rectum) and Dukes' C tumors alone, the corresponding results were as follows: 11.5% vs 6.8% and 22.2% vs 6.9%, respectively. Death from progressive cancer disease occurred in 14.4% vs 12.1% of all patients: 15.8% vs 8.5% (colon) and 25.4% vs 15.5% (Dukes' C), respectively. The follow-up time is too short for statistical analysis, however.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01298047
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Phase I trial of 4′-deoxydoxorubicin given weekly (1984)
    Springer
    Investigational new drugs 2 (1984), S. 369-374 
    Details
    ISSN: 1573-0646
    Keywords: Phase I trial ; 4′-deoxydoxorubicin ; esorubicin
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Twenty-six patients with various solid tumors entered a Phase I trial with 4′ -Deoxydoxorubicin (Esorubicin, IMI-58), a new doxorubicin analogue. The drug was administered weekly i.v. for 3–4 weeks. Leukopenia proved to be dose limiting. The maximum tolerated dose (MTD) was reached at 20 mg/m2 weekly for 3 weeks. For Phase II trials, a weekly dose of 15 and 17.5 mg/m2 can be proposed for poor and good risk patients respectively. Non-hematologic toxicity was minimal. Phase II trials with this new anthracycline are warranted.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00171587
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...